Cardiovascular drug delivery with ultrasound and microbubbles

Evan Unger, Thomas Porter, Jonathan Lindner, Paul Grayburn

    Research output: Contribution to journalArticle

    98 Citations (Scopus)

    Abstract

    Microbubbles lower the threshold for cavitation of ultrasound and have multiple potential therapeutic applications in the cardiovascular system. One of the first therapeutic applications to enter into clinical trials has been microbubble-enhanced sonothrombolysis. Trials were conducted in acute ischemic stroke and clinical trials are currently underway for sonothrombolysis in treatment of acute myocardial infarction. Microbubbles can be targeted to epitopes expressed on endothelial cells and thrombi by incorporating targeting ligands onto the surface of the microbubbles. Targeted microbubbles have applications as molecular imaging contrast agents and also for drug and gene delivery. A number of groups have shown that ultrasound with microbubbles can be used for gene delivery yielding robust gene expression in the target tissue. Work has progressed to primate studies showing delivery of therapeutic genes to generate islet cells in the pancreas to potentially cure diabetes. Microbubbles also hold potential as oxygen therapeutics and have shown promising results as a neuroprotectant in an ischemic stroke model. Regulatory considerations impact the successful clinical development of therapeutic applications of microbubbles with ultrasound. This paper briefly reviews the field and suggests avenues for further development.

    Original languageEnglish (US)
    Pages (from-to)110-126
    Number of pages17
    JournalAdvanced Drug Delivery Reviews
    Volume72
    DOIs
    StatePublished - Jun 15 2014

    Fingerprint

    Cardiovascular Agents
    Microbubbles
    Stroke
    Clinical Trials
    Genes
    Therapeutics
    Molecular Imaging
    Neuroprotective Agents
    Cardiovascular System
    Islets of Langerhans
    Contrast Media
    Primates
    Epitopes
    Pancreas
    Thrombosis
    Endothelial Cells
    Myocardial Infarction
    Oxygen
    Ligands
    Gene Expression

    Keywords

    • Cardiovascular
    • Drug delivery
    • Fluorocarbons
    • Gene delivery
    • Microbubbles
    • Oxygen delivery
    • Perfluorobutane
    • Perfluoropentane
    • Perfluoropropane
    • Sonothrombolysis
    • Ultrasound

    ASJC Scopus subject areas

    • Pharmaceutical Science
    • Medicine(all)

    Cite this

    Cardiovascular drug delivery with ultrasound and microbubbles. / Unger, Evan; Porter, Thomas; Lindner, Jonathan; Grayburn, Paul.

    In: Advanced Drug Delivery Reviews, Vol. 72, 15.06.2014, p. 110-126.

    Research output: Contribution to journalArticle

    Unger, Evan ; Porter, Thomas ; Lindner, Jonathan ; Grayburn, Paul. / Cardiovascular drug delivery with ultrasound and microbubbles. In: Advanced Drug Delivery Reviews. 2014 ; Vol. 72. pp. 110-126.
    @article{6d6c985747c741dda797b64588296dc5,
    title = "Cardiovascular drug delivery with ultrasound and microbubbles",
    abstract = "Microbubbles lower the threshold for cavitation of ultrasound and have multiple potential therapeutic applications in the cardiovascular system. One of the first therapeutic applications to enter into clinical trials has been microbubble-enhanced sonothrombolysis. Trials were conducted in acute ischemic stroke and clinical trials are currently underway for sonothrombolysis in treatment of acute myocardial infarction. Microbubbles can be targeted to epitopes expressed on endothelial cells and thrombi by incorporating targeting ligands onto the surface of the microbubbles. Targeted microbubbles have applications as molecular imaging contrast agents and also for drug and gene delivery. A number of groups have shown that ultrasound with microbubbles can be used for gene delivery yielding robust gene expression in the target tissue. Work has progressed to primate studies showing delivery of therapeutic genes to generate islet cells in the pancreas to potentially cure diabetes. Microbubbles also hold potential as oxygen therapeutics and have shown promising results as a neuroprotectant in an ischemic stroke model. Regulatory considerations impact the successful clinical development of therapeutic applications of microbubbles with ultrasound. This paper briefly reviews the field and suggests avenues for further development.",
    keywords = "Cardiovascular, Drug delivery, Fluorocarbons, Gene delivery, Microbubbles, Oxygen delivery, Perfluorobutane, Perfluoropentane, Perfluoropropane, Sonothrombolysis, Ultrasound",
    author = "Evan Unger and Thomas Porter and Jonathan Lindner and Paul Grayburn",
    year = "2014",
    month = "6",
    day = "15",
    doi = "10.1016/j.addr.2014.01.012",
    language = "English (US)",
    volume = "72",
    pages = "110--126",
    journal = "Advanced Drug Delivery Reviews",
    issn = "0169-409X",
    publisher = "Elsevier",

    }

    TY - JOUR

    T1 - Cardiovascular drug delivery with ultrasound and microbubbles

    AU - Unger, Evan

    AU - Porter, Thomas

    AU - Lindner, Jonathan

    AU - Grayburn, Paul

    PY - 2014/6/15

    Y1 - 2014/6/15

    N2 - Microbubbles lower the threshold for cavitation of ultrasound and have multiple potential therapeutic applications in the cardiovascular system. One of the first therapeutic applications to enter into clinical trials has been microbubble-enhanced sonothrombolysis. Trials were conducted in acute ischemic stroke and clinical trials are currently underway for sonothrombolysis in treatment of acute myocardial infarction. Microbubbles can be targeted to epitopes expressed on endothelial cells and thrombi by incorporating targeting ligands onto the surface of the microbubbles. Targeted microbubbles have applications as molecular imaging contrast agents and also for drug and gene delivery. A number of groups have shown that ultrasound with microbubbles can be used for gene delivery yielding robust gene expression in the target tissue. Work has progressed to primate studies showing delivery of therapeutic genes to generate islet cells in the pancreas to potentially cure diabetes. Microbubbles also hold potential as oxygen therapeutics and have shown promising results as a neuroprotectant in an ischemic stroke model. Regulatory considerations impact the successful clinical development of therapeutic applications of microbubbles with ultrasound. This paper briefly reviews the field and suggests avenues for further development.

    AB - Microbubbles lower the threshold for cavitation of ultrasound and have multiple potential therapeutic applications in the cardiovascular system. One of the first therapeutic applications to enter into clinical trials has been microbubble-enhanced sonothrombolysis. Trials were conducted in acute ischemic stroke and clinical trials are currently underway for sonothrombolysis in treatment of acute myocardial infarction. Microbubbles can be targeted to epitopes expressed on endothelial cells and thrombi by incorporating targeting ligands onto the surface of the microbubbles. Targeted microbubbles have applications as molecular imaging contrast agents and also for drug and gene delivery. A number of groups have shown that ultrasound with microbubbles can be used for gene delivery yielding robust gene expression in the target tissue. Work has progressed to primate studies showing delivery of therapeutic genes to generate islet cells in the pancreas to potentially cure diabetes. Microbubbles also hold potential as oxygen therapeutics and have shown promising results as a neuroprotectant in an ischemic stroke model. Regulatory considerations impact the successful clinical development of therapeutic applications of microbubbles with ultrasound. This paper briefly reviews the field and suggests avenues for further development.

    KW - Cardiovascular

    KW - Drug delivery

    KW - Fluorocarbons

    KW - Gene delivery

    KW - Microbubbles

    KW - Oxygen delivery

    KW - Perfluorobutane

    KW - Perfluoropentane

    KW - Perfluoropropane

    KW - Sonothrombolysis

    KW - Ultrasound

    UR - http://www.scopus.com/inward/record.url?scp=84901633696&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84901633696&partnerID=8YFLogxK

    U2 - 10.1016/j.addr.2014.01.012

    DO - 10.1016/j.addr.2014.01.012

    M3 - Article

    C2 - 24524934

    AN - SCOPUS:84901633696

    VL - 72

    SP - 110

    EP - 126

    JO - Advanced Drug Delivery Reviews

    JF - Advanced Drug Delivery Reviews

    SN - 0169-409X

    ER -